No Data
No Data
Express News | Neuropace Inc : Leerink Partners Cuts Target Price to $18 From $20
NeuroPace Is Maintained at Equal-Weight by Morgan Stanley
NeuroPace Is Maintained at Equal-Weight by Morgan
NeuroPace Price Target Cut to $8.00/Share From $9.50 by Morgan Stanley
NeuroPace Price Target Cut to $8.00/Share From $9.50 by Morgan
Express News | Neuropace Inc : Morgan Stanley Cuts Target Price to $8.00 From $9.50
Morgan Stanley Maintains NeuroPace(NPCE.US) With Hold Rating, Cuts Target Price to $8
Morgan Stanley analyst Drew Ranieri maintains $NeuroPace(NPCE.US)$ with a hold rating, and adjusts the target price from $9.5 to $8.According to TipRanks data, the analyst has a success rate of 39.4%
Morgan Stanley Lowers Price Target on NeuroPace to $8 From $9.50, Keeps Equalweight Rating
NeuroPace (NPCE) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $8 to $20.
No Data